Anti-angiogenic activity of heparin functionalised cerium oxide nanoparticles

Biomaterials

Volumn 34, Issue 34, 2013, Pages 8808-8818

  Lord, Megan S ^a   Tsoi, Bonny ^a   Gunawan, Cindy ^a   Teoh, Wey Yang ^b   Amal, Rose ^a   Whitelock, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiogenesis; Cerium oxide; Endothelial cells; Heparin; Nanoparticle; Reactive oxygen species

Indexed keywords

3-AMINOPROPYLTRIETHOXYSILANE; ANGIOGENESIS; ANTI-ANGIOGENIC ACTIVITY; CERIUM OXIDE NANOPARTICLE; CERIUM OXIDES; HEPARIN; REACTIVE OXYGEN SPECIES; SURFACE FUNCTIONALISATION;

CELL PROLIFERATION; CYTOLOGY; ENDOTHELIAL CELLS; NANOPARTICLES; OXIDES; OXYGEN; SILANES;

POLYSACCHARIDES;

3 AMINOPROPYLTRIETHOXYSILANE; CERIUM OXIDE; GROWTH FACTOR; HEPARANASE; HEPARIN; HEPARIN FUNCTIONALIZED CERIUM OXIDE NANOPARTICLE; NANOPARTICLE; REACTIVE OXYGEN METABOLITE; SILANE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME SYNTHESIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LYSOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANGIOGENESIS; CERIUM OXIDE; ENDOTHELIAL CELLS; HEPARIN; NANOPARTICLE; REACTIVE OXYGEN SPECIES;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CERIUM; ENDOTHELIAL CELLS; HEPARIN; HUMANS; LYSOSOMES; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SILANES;

EID: 84882834729     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.083     Document Type: Article

References (58)

1. Lord M.S., Jung M., Teoh W.Y., Gunawan C., Vassie J., Amal R., et al. Cellular uptake and and reactive oxygen species modulation of cerium oxide nanoparticles in human monocyte cell line U937. Biomaterials 2012, 33:7915-7924.
2. Asati A., Santra S., Kaittanis C., Perez J.M. Surface-charge-dependent cell localisation and cytotoxicity of cerium oxide nanoparticles. ACS Nano 2010, 4:5321-5331.
3. 3+ ions determine redox-dependent anti-apoptotic effect of cerium oxide nanoparticles. ACS Nano 2011, 5:4537-4549.
4. Pirmohamed T., Dowding J.M., Singh S., Wasserman B., Heckert E., Karakoti A.S., et al. Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem Commun 2010, 46:2736-2738.
5. Ting S.R.S., Whitelock J.M., Tomic R., Gunawan C., Teoh W.Y., Amal R., et al. Cellular uptake and activity of heparin functionlised cerium oxide nanoparticles in monocytes. Biomaterials 2013, 34:4377-4386.
6. Chen J., Patil S., Seal S., McGinnis J.F. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006, 1:142-150.
7. Schubert D., Dargusch R., Raitano J., Chan S.W. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem Biophys Res Commun 2006, 342:86-91.
8. Tarnuzzer R.W., Colon J., Patil S., Seal S. Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett 2005, 5:2573-2577.
9. Das D.K., Maulik N. Evaluation of antioxidant effectiveness in ischemiareperfusion tissue injury methods. Meth Enzymol 1994, 233:601-610.
10. Das S., Singh S., Dowding J.M., Oommen S., Kumar A., Sayle T.X.T., et al. The induction of angiogenesis by cerium oxide nanoparticles through the modulation of oxygen in intracellular environments. Biomaterials 2012, 33:7746-7755.
11. Chigurupati S., Mughal M.R., Okun E., Das S., Kumar A., McCaffery M., et al. Effects of cerium oxide nanoparticles on the growth of keratinocytes, fibroblasts and vascular endothelial cells in cutaneous wound healing. Biomaterials 2013, 34:2194-2201.
12. Giri S., Karakoti A.S., Graham R.P., Maguire J.L., Reilly C.M., Seal S., et al. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLOS One 2013, 8:e54578.
13. Ushio-Fukai M., Alexander R.W. Reactive oxygen species as mediators of angiogenesis signaling. Role of NAD(P)H oxidase. Mol Cell Biochem 2004, 264:85-97.
14. Monte M., Davel L.E., De Lustig E.S. Inhibition of lymphocyte-induced angiogenesis by free radical scavengers. Free Radic Biol Med 1994, 17:259-266.
15. Koch A.E., Cho M., Burrows J.C., Polverini P.J., Leibovich S.J. Inhibition of production of monocyte/macrophage-derived angiogenic activity by oxygen free radical scavengers. Cell Biol Int Rep 1992, 16:415-425.
16. Shono T., Ono M., Izumi H., Jimi S.-I., Matsushima K., Okamoto T., et al. Involvement of the transcription factor NF-kB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996, 16:4321-4329.
17. Taylor B.M., Fleming W.E., Benjamin C.W., Wu Y., Mathews W.R., Sun F.F. The mechanism of cytoprotective action of lazaroids I: inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. JPharmacol Exp Ther 1996, 276:1224-1231.
18. Maulik N., Das D.K. Redox signaling in vascular angiogenesis. Free Radic Biol Med 2002, 33:1047-1060.
19. Sasaki T., Yamada K., Otsuki H., Yuguchi T., Kohmura E., Hayakawa T. Brief exposure to hyposia induced bFGF mRNA and protein and protects rat cortical neurons from prolonged hypoix stress. Neurosci Res 1995, 23:289-296.
20. 2 in rat heart endothelial cells. Free Radic Biol Med 1998, 25:891-897.
21. Whitelock J.M., Melrose J. Heparan sulfate proteoglycans in healthy and diseased systems. Wiley Interdiscip Rev Syst Biol Med 2011, 3:739-751.
22. Whitelock J.M., Iozzo R.V. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005, 105:2745-2764.
23. Gohji K., Katsuoka Y., Okamoto M., Kamidono S., Kitazawa S., Toyoshima M., et al. Human heparanase: roles in invasion and metastasis of cancer. Acta Urologica Japonica 2000, 46:757-762.
24. Gingis-Velitski S., Zetser A., Flugelman M.Y., Vlodavsky I., Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. JBiol Chem 2004, 279:23536-23541.
25. Rao G., Ding H.G., Huang W., Le D., Maxhimer J.B., Oosterhof A., et al. Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetolgia 2011, 54:1527-1538.
26. Han H., Woytowich A.E., Manda A.K., Hievert L.M. Exp Biol Med 2007, 232:927-934.
27. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. JCell Mol Med 2011, 15:1013-1031.
28. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
29. Gupta A.K., Naregalkar R.R., Vaidya V.D., Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2007, 2:23-39.
30. Tan W., Wang K., He X., Zhao X.J., Drake T., Wang L., et al. Bionanotechnology based on silica nanoparticles. Med Res Rev 2004, 24:621-638.
31. de la Fuente J.M., Penadés S. Glyconanoparticles: types, synthesis and applications in glycoscience, biomedicine and material science. Biochem Biophys Acta 2006, 1760:636-651.
32. Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003, 55:403-419.
33. Lord M.S., Whitelock J.M. Recombinant production of proteoglycans and their bioactive domains. FEBS J 2013, 280:2490-2510.
34. Reyes-Ortega F., Rodriguez G., Rosa Aguilar M., Lord M., Whitelock J., Stenzel M.H., et al. Encapsulation of low molecular weight heparin (bemiparin) into polymeric nanoparticles obtained from cationic block copolymers: properties and cell activity. JMater Chem B 2013, 1:850-860.
35. Zhao Y., Lord M.S., Stenzel M.H. Apolyion complex micelle with heparin for growth factor delivery and uptake into cells. JMater Chem B 2013, 1:1635-1643.
36. Lee J., Jung M.J., Hwang Y.H., Lee Y.J., Lee S., Shin H. Heparin-coated superparamagnetic iron oxide for invivo MR imaging of human MSCs. Biomaterials 2012, 33:4861-4871.
37. Berry D., Lynn D.M., Sasisekharan R., Langer B. Poly(β-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem Biol 2004, 11:487-498.
38. Khorana A.A., Sahni A., Altland O.D., Francis C.W. Heparin inihibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003, 23:2110-2115.
39. Ludwig R.J. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol 2009, 6:281-289.
40. Manduteanu I., Voinea M., Antohe F., Dragomir E., Capraru M., Radulescu L., et al. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol 2003, 477:269-276.
41. Ornitz D.M., Yayon A., Flanagan J.G., Svahn C.M., Levi E., Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992, 12:240-247.
42. Stark W.J., Maciejewski M., Madler L., Pratsinis S.E., Baiker A. Flame-made nanocrystalline ceria/zirconia: structural properties and dynamic oxygen exchange capacity. JCatal 2003, 220:35-43.
43. Dowding J.M., Das S., Kumar A., Dosani T., McCormack R., Gupta A., et al. Cellular interaction and toxicity depend on physiochemical properties and surface modification of redox-active nanomaterials. ACS Nano 2013, 7:4855-4868.
44. Guler T., Polat Z.A., yayci E., Atacag T., Cetin A. Effects of low molecular weight heparins and unfractionated heparin on viability of human umbilical vein endothelial cells. Arch Gynecol Obstet 2013, 287:217-222.
45. Bae K.H., Moon C.W., Lee Y., Park T.G. Intracellular delivery of heparin complexed with chitosan-g-poly(ethylene glycol) for inducing apoptosis. Pharm Res 2009, 26:93-100.
46. Kolset S.O., Tviet H. Serglycin - structure and biology. Cell Mol Life Sci 2008, 65:1073-1085.
47. Spyridopoulos I., Brogi E., Kearney M., Sullivan A.B., Cetrulo C., Isner J.M., et al. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha. balance between growth and death signals. JMol Cell Cardiol 1997, 29:1321-1330.
48. Martin P., Leibovich S.J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005, 15:599-607.
49. Dandona P., Qutob T., Hamouda W., Bakri F., Aljada A., Kumbkarni Y. Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes. Thromb Res 1999, 96:437-443.
50. Trindade E.S., Boucas R.I., Rocha H.A., Dominato J.A., Paredes-Gamero E.J., Franco C.R., et al. Internalization and degradation of heparin is not required for stimulus of heparan sulfate proteoglycan synthesis. JCell Physiol 2008, 217:360-366.
51. Asati A., Santra S., Kaittanis C., Nath S., Perez J.M. Oxidase-like activity of polymer-coated cerium oxide nanoparticles. Angew Chem Int Ed 2009, 48:2308-2312.
52. Perez J.M., Asati A., Nath S., Kaittanis C. Synthesis of biocompatible dextran-coated nanoceria with pH-dependent antioxidant properties. Small 2008, 4:552-556.
53. Raats C.J., Bakker M.A., van den Born J., Berden J.H. Hydroxyl radicals depolymerise glomerular heparan sulfate invitro and in experimental nephrotic syndrome. JBiol Chem 1997, 272:26734-26741.
54. Naggi A., Casu B., Perez M., Torri G., Cassinelli G., Penco S., et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. JBiol Chem 2005, 280:12103-12113.
55. Irimura T., Nakajima M., Nicolson G.L. Chemically modified heparins as inhibitors of heparan sulfate specific endo-β-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 1986, 25:5322-5328.
56. Zhang W., Swanson R., Izaguirre G., Xiong Y., Lau L.F., Olson S.T. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005, 106:1621-1628.
57. Sasaki T., Larsson H., Kreuger J., Salmivirta M., Claesson-Welsh L., Lindahl U., et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 1999, 18:6240-6248.
58. Gengrinovitch S., Greenberg S.M., Cohen T., Gitay-Goren H., Rockwell P., Maione T.E., et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. JBiol Chem 1995, 270:15059-15065.